Adenocarcinoma | Prostate carcinoma | androgen independent prostate cancer | Serum testosterone measurement Level Decreased | Disease Progression | Measurable Disease | Evaluable Disease | Raised prostate specific antigen | Age | oxaliplatin
Item
must have histologically or cytologically confirmed adenocarcinoma consistent clinically and histologically with carcinoma of the prostate confirmed androgen independent prostate cancer (progression despite castrate levels of serum testosterone) measurable or evaluable disease (psa elevation will constitute evaluable disease) 18 years of age. because no dosing or adverse event data are currently available on the use of oxaliplatin in patients < 18 years of age, they are excluded from this study.
boolean
C0001418 (UMLS CUI [1])
C0600139 (UMLS CUI [2])
C1654637 (UMLS CUI [3])
C0428413 (UMLS CUI [4,1])
C0441889 (UMLS CUI [4,2])
C0205216 (UMLS CUI [4,3])
C0242656 (UMLS CUI [5])
C1513041 (UMLS CUI [6])
C1516986 (UMLS CUI [7])
C0178415 (UMLS CUI [8])
C0001779 (UMLS CUI [9])
C0069717 (UMLS CUI [10])
Life Expectancy | ECOG performance status | Cytotoxic Chemotherapy Quantity | androgen suppression | Male Castration | Luteinizing Hormone-releasing Hormone Agonist | Androgen Antagonists
Item
life expectancy of greater than 3 months. ecog performance status of 0-1. no more than 2 prior regimens of cytotoxic chemotherapy. androgen deprivation (castration or lhrh analogue), and prior antiandrogens allowed.
boolean
C0023671 (UMLS CUI [1])
C1520224 (UMLS CUI [2])
C0677881 (UMLS CUI [3,1])
C1265611 (UMLS CUI [3,2])
C1515985 (UMLS CUI [4])
C0007347 (UMLS CUI [5])
C1518041 (UMLS CUI [6])
C0002842 (UMLS CUI [7])
bicalutamide Discontinued | nilutamide Discontinued | Megestrol Discontinued | Flutamide Discontinued
Item
patients must be off bicalutamide or nilutamide > 42 days, megestrol or flutamide > 28 days.
boolean
C0285590 (UMLS CUI [1,1])
C1444662 (UMLS CUI [1,2])
C0068771 (UMLS CUI [2,1])
C1444662 (UMLS CUI [2,2])
C0025175 (UMLS CUI [3,1])
C1444662 (UMLS CUI [3,2])
C0016384 (UMLS CUI [4,1])
C1444662 (UMLS CUI [4,2])
Diphosphonates | Therapeutic radiology procedure Secondary malignant neoplasm of bone | Raised prostate specific antigen
Item
concurrent bisphosphonate therapy allowed. patients with prior radiotherapy for treatment of their bony metastases will be included if time since radiation is > 4 weeks, and if psa is clearly rising.
boolean
C0012544 (UMLS CUI [1])
C1522449 (UMLS CUI [2,1])
C0153690 (UMLS CUI [2,2])
C0178415 (UMLS CUI [3])
Organ function | White Blood Cell Count procedure | Absolute neutrophil count | Hemoglobin | Platelet Count measurement | Serum total bilirubin measurement | Aspartate aminotransferase measurement | Alanine aminotransferase measurement | Secondary malignant neoplasm of liver | Prothrombin time normal | Partial Thromboplastin Time measurement | Creatinine measurement, serum | Neurologic function | Peripheral Neuropathy Clinical Significance | Neuropathy CTCAE Grades
Item
patients must have acceptable organ function as defined as: :wbc > 2500/mm3 or anc > 1500/mm3, hemoglobin > 9.0 g/dl, platelet count > 100,000/mm3; bilirubin < 1.5 mg/dl, sgot/sgpt < 2 x uln (< 4 x uln if liver metastases present), pt/ptt normal; creatinine < 1.8 mg/dl adequate neurologic function defined as no clinically significant peripheral neuropathy, defined as any neuropathy ≤ grade 1.
boolean
C0678852 (UMLS CUI [1])
C0023508 (UMLS CUI [2])
C0948762 (UMLS CUI [3])
C0019046 (UMLS CUI [4])
C0032181 (UMLS CUI [5])
C1278039 (UMLS CUI [6])
C0201899 (UMLS CUI [7])
C0201836 (UMLS CUI [8])
C0494165 (UMLS CUI [9])
C0580551 (UMLS CUI [10])
C0030605 (UMLS CUI [11])
C0201976 (UMLS CUI [12])
C0027767 (UMLS CUI [13])
C0031117 (UMLS CUI [14,1])
C2826293 (UMLS CUI [14,2])
C0442874 (UMLS CUI [15,1])
C1516728 (UMLS CUI [15,2])
Normal cardiovascular function | Congestive heart failure | Angina Pectoris Uncontrolled | Myocardial Infarction
Item
adequate cardiovascular function defined as no active congestive heart failure, no uncontrolled angina, no myocardial infarction within the past 6 months.
boolean
C0232089 (UMLS CUI [1])
C0018802 (UMLS CUI [2])
C0002962 (UMLS CUI [3,1])
C0205318 (UMLS CUI [3,2])
C0027051 (UMLS CUI [4])
Therapies, Investigational | Cytotoxic Chemotherapy | Therapeutic radiology procedure | Investigational New Drugs
Item
no other experimental treatment, cytotoxics or radiation 4 weeks prior to enrollment. may not be taking other investigational drugs while on trial.
boolean
C0949266 (UMLS CUI [1])
C0677881 (UMLS CUI [2])
C1522449 (UMLS CUI [3])
C0013230 (UMLS CUI [4])
Metastatic malignant neoplasm to brain | Prognosis bad | Progressive neurologic dysfunction Interferes with Event Neurologic | Progressive neurologic dysfunction Interferes with Adverse event
Item
patients with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.
boolean
C0220650 (UMLS CUI [1])
C0278252 (UMLS CUI [2])
C4013375 (UMLS CUI [3,1])
C0521102 (UMLS CUI [3,2])
C0441471 (UMLS CUI [3,3])
C0205494 (UMLS CUI [3,4])
C4013375 (UMLS CUI [4,1])
C0521102 (UMLS CUI [4,2])
C0877248 (UMLS CUI [4,3])
oxaliplatin | Allergic Reaction Investigational New Drugs | Allergic Reaction Compound Similar
Item
no prior therapy with oxaliplatin is allowed. no history of allergic reactions attributed to the drugs used in this study or compounds of similar chemical or biologic composition.
boolean
C0069717 (UMLS CUI [1])
C1527304 (UMLS CUI [2,1])
C0013230 (UMLS CUI [2,2])
C1527304 (UMLS CUI [3,1])
C1706082 (UMLS CUI [3,2])
C2348205 (UMLS CUI [3,3])
intolerance to Antiemetics | Hypersensitivity Antiemetics | Investigational New Drugs | intolerance to 5-HT>3< receptor antagonist | Hypersensitivity 5-HT>3< receptor antagonist
Item
no history of intolerance or allergy to the antiemetics to be administered in conjunction with the study drugs (i.e., 5 ht3 antagonists).
boolean
C1744706 (UMLS CUI [1,1])
C0003297 (UMLS CUI [1,2])
C0020517 (UMLS CUI [2,1])
C0003297 (UMLS CUI [2,2])
C0013230 (UMLS CUI [3])
C1744706 (UMLS CUI [4,1])
C0360055 (UMLS CUI [4,2])
C0020517 (UMLS CUI [5,1])
C0360055 (UMLS CUI [5,2])
Malignant Neoplasm Site Primary | Squamous cell carcinoma of skin | Basal cell carcinoma
Item
no concurrent other active cancer from another primary site, except squamous cell and basal cell carcinoma of the skin.
boolean
C0006826 (UMLS CUI [1,1])
C1515974 (UMLS CUI [1,2])
C0205225 (UMLS CUI [1,3])
C0553723 (UMLS CUI [2])
C0007117 (UMLS CUI [3])
Comorbidity | Pneumonia, Interstitial | Pulmonary Fibrosis Extensive Symptomatic | Uncontrolled hypertension | Angina, Unstable | Symptomatic congestive heart failure New York Heart Association Classification | Cardiac Arrhythmia Serious | Diabetic - poor control | Communicable Disease
Item
no other serious concomitant illness will be allowed, including interstitial pneumonia, extensive and symptomatic fibrosis of the lung, uncontrolled hypertension, unstable angina, symptomatic congestive heart failure, nyha class iii or iv, serious cardiac arrhythmia, uncontrolled diabetes mellitus or active infection.
boolean
C0009488 (UMLS CUI [1])
C0206061 (UMLS CUI [2])
C0034069 (UMLS CUI [3,1])
C0205231 (UMLS CUI [3,2])
C0231220 (UMLS CUI [3,3])
C1868885 (UMLS CUI [4])
C0002965 (UMLS CUI [5])
C0742758 (UMLS CUI [6,1])
C1275491 (UMLS CUI [6,2])
C0003811 (UMLS CUI [7,1])
C0205404 (UMLS CUI [7,2])
C0421258 (UMLS CUI [8])
C0009450 (UMLS CUI [9])